Salvage cryotherapy for localized recurrence of prostate cancer (PCa) following primary radiation treatment is associated with a durable response, with high rates of cancer-specific and metastasis-free survival, according to data presented at the Canadian Urological Association’s 74th Annual Meeting in Quebec City.
The findings, presented by Haider Abed, a medical student at the University of Western Ontario in London, are from a study of 187 patients who underwent salvage cryotherapy for radiorecurrent PCa and had a median follow-up duration of 12 years. Prior to salvage treatment, patients had a median age of 71 years and median PSA level of 11 ng/mL.
The 12-year cancer-specific, metastasis-free, and overall survival rates were 81%, 78%, and 56%, respectively, the investigators reported in a poster presentation. The 12-year rate of freedom from castration-resistant PCa was 80%. The median time to recurrence was 58 months, with a median time to initiation of androgen deprivation therapy (ADT) of 101 months. At the end of follow-up, 91 patients (48.7%) were free of ADT.
Pre-salvage age and post-salvage PSA nadir predicted overall mortality, according to the investigators. On multivariable analysis, pre-radiation Gleason score 8-10, stage (T3a-T4) disease, pre-salvage PSA, and post-salvage PSA nadir predicted cancer-specific survival.
“Salvage treatment can achieve ADT-free status in selected patients and delay the need for ADT in those who subsequently develop systemic disease,” the investigators concluded in their study abstract.
Nair SM, Peters M, Abed H, et al. Tumor control outcomes of salvage cryotherapy for radiorecurrent prostate cancer at median 12 years follow-up. Presented at the Canadian Urological Association’s 74th Annual Meeting in Quebec City, June 29 to July 1. Poster MP-4.13.
This article originally appeared on Renal and Urology News